JW (Cayman) Therapeutics Co. Ltd.HKEX: 2126

Subscription of new shares under general mandate

· Issued by JW (Cayman) Therapeutics Co. Ltd. via HKEXnews

Filed with HKEX · Stock code 2126 · · 12 pages · English

Summary by 6ix AI

JW (Cayman) Therapeutics Co. Ltd. has announced a subscription agreement to issue new shares under a general mandate, involving two institutional investors subscribing for a significant number of shares at a specified price. The total gross proceeds from this subscription are expected to be substantial, with net proceeds estimated after deducting related expenses. The company plans to use the proceeds for research and development of its CAR-T pipeline and to enhance its manufacturing capabilities. Completion of the subscription is subject to certain conditions being met, and shareholders are advised to exercise caution in their dealings.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

JW (Cayman) Therapeutics Co. Ltd. on 6ix

Earlier from JW (Cayman) Therapeutics

All JW (Cayman) Therapeutics news releases